Inclusion Body Myositis Pipeline Review and Therapeutics Development Market Research Report for H2 2015

Nov 02, 2015, 21:00 ET from Life Science Industry Research

PUNE, India, November 3, 2015 /PRNewswire/ --

New market research titled "Inclusion Body Myositis (IBM) - Pipeline Review, H2 2015" providing an overview and in-depth analysis of inclusion body myositis therapeutic pipeline from across the world is now available with

This report provides comprehensive information on the therapeutic development for Inclusion Body Myositis (IBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inclusion Body Myositis (IBM) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on H2 2015 pipeline review of Inclusion Body Myositis (IBM) with 21 market data tables and 13 figures, spread across 59 pages is available at .

Companies discussed in this report include Acceleron Pharma, Inc., Escala Therapeutics, Inc., Novartis AG and Ultragenyx Pharmaceutical Inc. Drugs Profiles cover in this report are AAV1-Foliistatin, ACE-083, aceneuramic acid, bimagrumab, DEXM-74, Gene Therapy for Hereditary Inclusion Body Myopathy and UX-007.

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Inclusion Body Myositis (IBM) and reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities and also key players involved in the therapeutics development for Inclusion Body Myositis (IBM) and enlists all their major and minor projects summarizing all the dormant and discontinued pipeline projects. A review of the Inclusion Body Myositis (IBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources, pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Inclusion Body Myositis (IBM) pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products.

Order a copy of Inclusion Body Myositis (IBM) - Pipeline Review, H2 2015 report @ .

Another newly published market research report titled on EpiCast Report: Growth Hormone Deficiency - Epidemiology Forecast to 2024 provides an overview of the risk factors and global trends of GHD in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the GHD diagnosed in children (=18 years) and in adults (>18 years) segmented by sex from 2014-2024. The forecast also provides GHD diagnosed cases in children segmented by the etiological classifications (idiopathic and organic; organic further segmented into congenital and acquired). The forecast for GHD diagnosed in adults are further segmented by etiological classifications (idiopathic and acquired). Growth Hormone Deficiency - Epidemiology Forecast to 2024 market research report is available at .

More reports on Pharmaceuticals are available at .

About Us: is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel:  +1-888-391-5441

Connect with Us:  

G+ / Google Plus:



RSS / Feeds:

SOURCE Life Science Industry Research